Search
NTx-265
go.drugbank.com/drugs/DB05649InvestigationalIn May 2006, biotechnology company Stem Cell Therapeutics started a Phase IIa study of NTx-265. … NTx-265 is a combination of two currently marketed large molecules designed to stimulate the growth and differentiation of neural stem cells in adults who have suffered a stroke – the second leading cause
AMGN-0007
go.drugbank.com/drugs/DB06511ExperimentalRecombinant osteoprotegerin (AMGN-0007) is a recombinant OPG construct developed as a potential therapeutic agent in the treatment of bone disease.
Stamulumab
go.drugbank.com/drugs/DB05915InvestigationalMYO-029 is a human anti-GDF-8 monoclonal antibody, which is being developed to treat muscle-wasting diseases including muscular dystrophy and age-related sarcopenia.
CRx-139
go.drugbank.com/drugs/DB05744ExperimentalIt is a dissociated steroid designed to enhance the immuno-modulatory activity of a low-dose glucocorticoid steroid without a comparable increase in steroid-related side effects. … CRx-139 is an oral synergistic combination drug candidates with novel mechanisms of action targeting multiple biological pathways simultaneously.
Solenopsis richteri
go.drugbank.com/drugs/DB11026ApprovedSolenopsis richteri allergenic extract is used in allergenic testing. It is extracted from the black imported fire ant which is native to South Amercia. … The species has also been introduced in North Amercia. When stung, the bites are characterized by sterile pustules that are surrounded by reddened swelling along with redness extending beyond.
Amuvatinib
go.drugbank.com/drugs/DB12742InvestigationalAmuvatinib has been used in trials studying the treatment of Solid Tumors and Small Cell Lung Carcinoma. … Amuvatinib also suppresses Rad51 protein, a critical component of double-stranded DNA repair in cancer cells.
Synonyms: 1-Piperazinecarbothioamide, N-(1,3-benzodioxol-5-ylmethyl)-4-benzofuro(3,2-d)pyrimidin-4-yl-, 4-[1]Benzofuro[3,2-D]Pyrimidin-4-Yl-N-(1,3-Benzodioxol-5-Ylmethyl)Piperazine-1-CarbothioamideDLO6002
go.drugbank.com/drugs/DB05179ExperimentalDLO6002 is developed by Summit Corporation and is in phase I of clinical trials for the treatment of Parkinson's disease.
Norflurane
go.drugbank.com/drugs/DB13116ApprovedInvestigationalWithdrawnNorflurane is under investigation in clinical trial NCT01673061 (Vapocoolant Spray for Numbing Small Boils Before Incision and Drainage).